# Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
Canonical URL: https://biopharmsignal.com/news/GPCR/structure-therapeutics-reports-first-quarter-2026-financial-results-and-recent-highlights
Ticker: GPCR
Company: Structure Therapeutics
Source: Structure Therapeutics
Published: 2026-05-07 20:06 EST
Original Source URL: https://ir.structuretx.com
## Summary

Reported positive results from aleniglipron Phase 2 ACCESS II study  with up to 16.3% body weight loss, demonstrating highest efficacy among oral GLP-1RAs at the 44-week time point and potentially comparable efficacy to injectable GLP1-RAs Data from ACCESS OLE expected in Q3 2026; Data from the

## Article Body
Reported positive results from aleniglipron Phase 2 ACCESS II study  with up to 16.3% body weight loss, demonstrating highest efficacy among oral GLP-1RAs at the 44-week time point and potentially comparable efficacy to injectable GLP1-RAs Data from ACCESS OLE expected in Q3 2026; Data from the
## Recent Company News
- 2026-05-26 20:05 EST — [Structure Therapeutics Announces Participation in Upcoming Investor Conferences](https://biopharmsignal.com/news/GPCR/structure-therapeutics-announces-participation-in-upcoming-investor-conferences) — Source: Structure Therapeutics
- 2026-05-07 20:06 EST — [Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights](https://biopharmsignal.com/news/GPCR/structure-therapeutics-reports-first-quarter-2026-financial-results-and-recent-highlights) — Source: Structure Therapeutics
- 2026-04-27 20:05 EST — [Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions](https://biopharmsignal.com/news/GPCR/structure-therapeutics-to-present-aleniglipron-amylin-and-combination-data-at-the-american-diabetes-association-86th-scientific-sessions) — Source: Structure Therapeutics
- 2026-04-14 20:05 EST — [Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel](https://biopharmsignal.com/news/GPCR/structure-therapeutics-appoints-matthew-lang-j-d-as-chief-operating-officer-and-general-counsel) — Source: Structure Therapeutics
- 2026-03-16 11:00 EST — [Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron](https://biopharmsignal.com/news/GPCR/structure-therapeutics-reports-positive-topline-data-from-phase-2-access-ii-trial-with-once-daily-oral-small-molecule-glp-1-receptor-agonist-aleniglipron) — Source: Structure Therapeutics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)